Table I.
Clinical and pathological features of patients with primary cancer of the liver.
| Variable | Percentage (%) |
|---|---|
| No. of patients | 152 (100.0) |
| Gender | |
| Male | 122 (80.3) |
| Female | 30 (19.7) |
| Age, years | |
| ≤55 | 77 (50.7) |
| >55 | 75 (49.3) |
| Diameter, cm | |
| ≤5 | 86 (56.6) |
| >5 | 66 (43.4) |
| No. of tumors | |
| 1 | 136 (89.5) |
| ≥2 | 16 (10.5) |
| Cirrhosis | |
| + | 102 (67.1) |
| − | 50 (32.9) |
| HBsAg | |
| + | 139 (91.4) |
| − | 13 (8.6) |
| HBeAg | |
| + | 31 (20.4) |
| − | 121 (79.6) |
| AFP, µg/l | |
| ≤400 | 120 (79.0) |
| >400 | 32 (21) |
| CEA, µg/l | |
| ≤5 | 116 (76.3) |
| >5 | 36 (23.7) |
| Differentiation degree | |
| High | 32 (21.0) |
| Middle | 53 (34.9) |
| Low | 67 (44.1) |
| AJCC stage | |
| I | 131 (86.2) |
| II | 9 (5.9) |
| III | 10 (6.6) |
| IV | 2 (1.3) |
CRM1, chromosome region maintenance 1; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; AFP, α-fetoprotein; CEA, carcinoembryonic antigen; AJCC, American Joint Committee on Cancer; +, positive; -, negative.